Biocon retains economic interest in global commercialization of Hulio in-licensed by Mylan
Biocon is retaining economic interest in global commercialization of Hulio, (biosimilar Adalimumab) in-licensed by Mylan. Following the successful approval and European launch of Hulio, (biosimilar…